Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6081290 | 0.87 | MCL1 (0.34) | SMN1; SMN2MCL1ALDH1A1TSHRHPGD | |
| SCHEMBL6080111 | 0.84 | MEN1 (0.36) | MEN1KMT2AGAASMN1; SMN2AURKA | |
| SCHEMBL6081252 | 0.83 | MCL1 (0.34) | MEN1KMT2ASMN1; SMN2MCL1ALDH1A1 | |
| SCHEMBL6081135 | 0.83 | HPGD (0.36) | MEN1KMT2AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL6081113 | 0.82 | CTSS (0.38) | MCL1 | |
| SCHEMBL9705616 | 0.79 | MEN1 (0.45) | MEN1KMT2AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL6080663 | 0.78 | SMYD3 (0.37) | MEN1KMT2AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL18458829 | 0.77 | ALDH1A1 (0.50) | MEN1KMT2AGAASMN1; SMN2AURKA | |
| Ethane SCHEMBL20528153 | 0.77 | MEN1 (0.44) | MEN1KMT2AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL6081292 | 0.76 | MCL1 (0.36) | MCL1ALDH1A1L3MBTL1CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048891-A1 | METASUBSTITUTED THIAZOLIDINONES, THEIR MANUFACTURE AND USE AS A DRUG | SCHULZE KLAUSE | 2010-02-25 | — | — | US | disclosed |
| US-20100048891-A1 | METASUBSTITUTED THIAZOLIDINONES, THEIR MANUFACTURE AND USE AS A DRUG | SCHULZE KLAUSE | 2010-02-25 | — | — | US | disclosed |
| US-20100048891-A1 | METASUBSTITUTED THIAZOLIDINONES, THEIR MANUFACTURE AND USE AS A DRUG | SCHULZE KLAUSE | 2010-02-25 | — | — | US | disclosed |
| US-7511059-B2 | Thiazolidinones, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2009-03-31 | — | — | US | disclosed |
| US-7511059-B2 | Thiazolidinones, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2009-03-31 | — | — | US | disclosed |
| US-7511059-B2 | Thiazolidinones, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2009-03-31 | — | — | US | disclosed |
| US-20070037862-A1 | inhibitors of polo-like kinases; (4,4-Dimethyl-4,5-dihydro-oxazol-2-yl)-[3-ethyl-4-oxo-5-[1-[3-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetonitrile; cancer, auto-immune diseases, cardiovascular diseases | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037862-A1 | inhibitors of polo-like kinases; (4,4-Dimethyl-4,5-dihydro-oxazol-2-yl)-[3-ethyl-4-oxo-5-[1-[3-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetonitrile; cancer, auto-immune diseases, cardiovascular diseases | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037862-A1 | inhibitors of polo-like kinases; (4,4-Dimethyl-4,5-dihydro-oxazol-2-yl)-[3-ethyl-4-oxo-5-[1-[3-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetonitrile; cancer, auto-immune diseases, cardiovascular diseases | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-02-15 | — | — | US | disclosed |
| US-20070015759-A1 | Metasubstituted thiazolidinones, their manufacture and use as a drug | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-18 | — | — | US | disclosed |
| US-20070015759-A1 | Metasubstituted thiazolidinones, their manufacture and use as a drug | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-18 | — | — | US | disclosed |
| US-20070015759-A1 | Metasubstituted thiazolidinones, their manufacture and use as a drug | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-18 | — | — | US | disclosed |
| US-20060223833-A1 | Thiazolidinones, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-10-05 | — | — | US | disclosed |
| US-20060079503-A1 | Thiazolidinones and the use therof as polo-like kinase inhibitors | SCHERING AKTIENGESELLSCHAFT | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037862-A1 | inhibitors of polo-like kinases; (4,4-Dimethyl-4,5-dihydro-oxazol-2-yl)-[3-ethyl-4-oxo-5-[1-[3-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetonitrile; cancer, auto-immune diseases, cardiovascular diseases | PLK2, PLK4, PDXK | MEN1 3850/4885KMT2A 849/4885GAA 1502/4885 |
| US-20100048891-A1 | METASUBSTITUTED THIAZOLIDINONES, THEIR MANUFACTURE AND USE AS A DRUG | PLK2, PDXK, PLK4 | MEN1 3222/4885KMT2A 3012/4885GAA 815/4885 |
| US-20060079503-A1 | Thiazolidinones and the use therof as polo-like kinase inhibitors | PLK4, PLK2, PLK3 | MEN1 3800/4885KMT2A 3723/4885GAA 890/4885 |
| US-20060223833-A1 | Thiazolidinones, their production and use as pharmaceutical agents | PLK2, PLK4, PLK3 | MEN1 4624/4885KMT2A 3600/4885GAA 366/4885 |
| US-20070015759-A1 | Metasubstituted thiazolidinones, their manufacture and use as a drug | PLK4, PDXK, PLK2 | MEN1 3023/4885KMT2A 2543/4885GAA 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.